JP2023538521A5 - - Google Patents

Info

Publication number
JP2023538521A5
JP2023538521A5 JP2023507887A JP2023507887A JP2023538521A5 JP 2023538521 A5 JP2023538521 A5 JP 2023538521A5 JP 2023507887 A JP2023507887 A JP 2023507887A JP 2023507887 A JP2023507887 A JP 2023507887A JP 2023538521 A5 JP2023538521 A5 JP 2023538521A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
group
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044907 external-priority patent/WO2022032071A1/en
Publication of JP2023538521A publication Critical patent/JP2023538521A/ja
Publication of JP2023538521A5 publication Critical patent/JP2023538521A5/ja
Pending legal-status Critical Current

Links

JP2023507887A 2020-08-07 2021-08-06 キナーゼ阻害剤およびその使用 Pending JP2023538521A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
US63/063,113 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2023538521A JP2023538521A (ja) 2023-09-08
JP2023538521A5 true JP2023538521A5 (cg-RX-API-DMAC7.html) 2024-08-15

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507887A Pending JP2023538521A (ja) 2020-08-07 2021-08-06 キナーゼ阻害剤およびその使用

Country Status (10)

Country Link
US (1) US20230303570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192582A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538521A (cg-RX-API-DMAC7.html)
KR (1) KR20230112605A (cg-RX-API-DMAC7.html)
CN (1) CN116710453A (cg-RX-API-DMAC7.html)
AU (1) AU2021321536A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002248A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179671A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023001312A (cg-RX-API-DMAC7.html)
WO (1) WO2022032071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120129682A (zh) * 2022-08-25 2025-06-10 英莱汶公司 用于抑制raf激酶的萘啶化合物
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025064567A1 (en) * 2023-09-19 2025-03-27 Enliven Inc. Tricyclic phenols for inhibition of raf kinases
CN122555710A (zh) * 2024-01-15 2026-08-11 上海瑛派药业有限公司 Wee1抑制剂的晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2310657C2 (ru) * 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
CN109789143A (zh) * 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP7057798B2 (ja) mTORC1阻害剤
JP7394768B2 (ja) キナーゼ阻害剤としての環状イミノピリミジン誘導体
JP2018533611A5 (cg-RX-API-DMAC7.html)
US10759803B2 (en) Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP2010539095A5 (cg-RX-API-DMAC7.html)
JPWO2008001886A1 (ja) オーロラ(Aurora)阻害剤
WO2013173254A1 (en) Bicyclic compounds as kinases inhibitors
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
JP2014518544A5 (cg-RX-API-DMAC7.html)
JP2020506895A5 (cg-RX-API-DMAC7.html)
WO2012000421A1 (zh) 棉酚衍生物在制备抗肿瘤药物中的应用
JP2015515995A (ja) キナーゼ阻害剤として有用な置換アミノキナゾリン
CN110078730B (zh) 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
JP2006503079A (ja) 抗癌化合物
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
CA3130471A1 (en) Pan-raf kinase inhibitor and use thereof
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
WO2017180723A1 (en) Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
AU2015355965B2 (en) Novel PEG derivative
CN112442062B (zh) 一种柳胺酚有机硅化合物及抗肿瘤用途
JP2013510899A5 (cg-RX-API-DMAC7.html)
US12036215B2 (en) Antitumor agent and method for tumor therapy
JP2012087118A (ja) 抗腫瘍剤
CN111039940A (zh) 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途